A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

Phase 1/2 Study of Pemetrexed (Alimta) Plus Carboplatin, or Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients With Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer (NSCLC)

The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.

Inclusion Criteria:

• Inoperable non small cell lung cancer
• No weight loss greater than 10% in 3 months prior to enrolling in trial
• Adequate kidney function
• Adequate liver function
• Adequate lung function

Exclusion Criteria:

• Previous surgery to remove lung tumor
• Previous chemotherapy or radiation therapy or lung cancer
• Inability to take vitamin supplementation
• Heart attack within past 6 months
• Active infection